Citation Impact
Citing Papers
Topical tofacitinib for atopic dermatitis: a phase II a randomized trial
2016
Rheumatoid arthritis
2018 Standout
Rheumatoid arthritis
2016 Standout
The JAK/STAT signaling pathway: from bench to clinic
2021 Standout
Crohn's disease
2016 Standout
JAK–STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects
2017
The emerging safety profile of JAK inhibitors in rheumatic disease
2017
Safety of Janus Kinase Inhibitors in Patients With Inflammatory Bowel Diseases or Other Immune-mediated Diseases: A Systematic Review and Meta-Analysis
2020
NF-κB, inflammation, immunity and cancer: coming of age
2018 Standout
The JAK-STAT Pathway: Impact on Human Disease and Therapeutic Intervention
2015
Clinical efficacy of launched JAK inhibitors in rheumatoid arthritis
2018
JAK inhibition using tofacitinib for inflammatory bowel disease treatment: a hub for multiple inflammatory cytokines
2015
Janus kinase inhibitors: A therapeutic strategy for cancer and autoimmune diseases
2020
Selective JAK inhibitors in development for rheumatoid arthritis
2014
Inflammatory responses and inflammation-associated diseases in organs
2017 Standout
Works of M. Lamba being referenced
A randomized phase 2a efficacy and safety trial of the topical J anus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis
2013
Evaluation of the Effect of Tofacitinib Exposure on Outcomes in Kidney Transplant Patients
2015
THU0252 Relationship between Lymphocyte Count and Risk of Infection in Rheumatoid Arthritis Patients Treated with Tofacitinib
2013
THU0178 Relationship Between NK Cell Count and Important Safety Events in Rheumatoid Arthritis Patients Treated with Tofacitinib
2015